Mark B. McClellan

CIK: 0001567006

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

JNJ

JOHNSON & JOHNSON

Director

Cigna Group

Director

ALHC

Alignment Healthcare, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

JNJ
JOHNSON & JOHNSON
Apr 23, 2026
Award(A)
Deferred Share Units
Direct
975 shares-
CI
Cigna Group
Apr 22, 2026
Award(A)
Direct
782 shares-
ALHC
Alignment Healthcare, Inc.
Mar 13, 2026
Award(A)
Direct
13.1K shares-
JNJ
JOHNSON & JOHNSON
Apr 24, 2025
Award(A)
Deferred Share Units
Direct
1.3K shares-
CI
Cigna Group
Apr 23, 2025
Award(A)
Direct
638 shares-
ALHC
Alignment Healthcare, Inc.
Mar 13, 2025
Award(A)
Direct
12.3K shares-

		Type	Shares	Price		Ownership
Apr 23, 2026	JNJ JOHNSON & JOHNSON	Award(A) Deferred Share Units	975	-	-	Direct
Apr 22, 2026	CI Cigna Group	Award(A)	782	-	$0	Direct
Mar 13, 2026	ALHC Alignment Healthcare, Inc.	Award(A)	13,096	-	$0	Direct
Apr 24, 2025	JNJ JOHNSON & JOHNSON	Award(A) Deferred Share Units	1,316	-	-	Direct
Apr 23, 2025	CI Cigna Group	Award(A)	638	-	-	Direct
Mar 13, 2025	ALHC Alignment Healthcare, Inc.	Award(A)	12,258	-	-	Direct

1-6 of 6 transactions

About McClellan Mark B.

McClellan Mark B. (SEC CIK 0001567006) files insider reports with the SEC as Director of JOHNSON & JOHNSON (JNJ), Director of Cigna Group (CI) and Director of Alignment Healthcare, Inc. (ALHC).

Signal8 holds 6 ownership filings by McClellan Mark B., all Form 4s, filed between Mar 17, 2025 and Apr 27, 2026. Those filings report 6 transactions, from Mar 13, 2025 to Apr 23, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on McClellan Mark B.'s filings is in BLOOMFIELD, CT.

Recent filings by McClellan Mark B.

Apr 23, 2026: Grant or award of JNJ derivative securities (Form 4, code A).
Apr 22, 2026: Grant or award of CI shares (Form 4, code A).
Mar 13, 2026: Grant or award of ALHC shares (Form 4, code A).
Apr 24, 2025: Grant or award of JNJ derivative securities (Form 4, code A).
Apr 23, 2025: Grant or award of CI shares (Form 4, code A).

Other insiders filing for JOHNSON & JOHNSON (JNJ)

Pinto Daniel E, Director
Woods Eugene A., Director
HEWSON MARILLYN A, Director
Schmid Timothy, EVP, WW Chair, MedTech
Cavanaugh Thomas, EVP WW Chair, Innovative Med.
Taubert Jennifer L, EVP, WWC. Innovative Medicine

How to read Form 4 transaction codes